Drug Database
OL

OLipHEX delivery system

✓ Approved

PR Pharmaceuticals · therapeutic agent

What is OLipHEX delivery system?

OLipHEX delivery system is a therapeutic agent developed by PR Pharmaceuticals. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyPR Pharmaceuticals
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, PR Pharmaceuticals

Therapeutic Indications

OLipHEX delivery system is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Surgical and medical proceduresOral appliance application✓ Approved

Related Research Articles

PubMedJournal of healthcare leadership2026-09-20

Public Health Challenges in Somalia: Strengthening Health Systems for Resilient and Equitable Healthcare Delivery.

Mohamoud Jamal Hassan JH, Adam Mohamed Hussein MH, Sheikh Mohamed Ahmed Mahad AM

Somalia continues to face multidimensional public health challenges driven by prolonged conflict, political instability, fragmented governance, climate-related disasters, displacement, poverty, and a fragile health system. The country carries a dual burden of communicable and non-communicable diseases (NCDs), alongside persistently high maternal and child mortality and recurrent nutrition and WASH emergencies. These pressures are intensified by workforce shortages, limited laboratory and surveillance capacity, unequal access to care, and heavy dependence on externally financed programmes. In this perspective, health-system resilience refers to Somalia's capacity to anticipate, absorb, adapt to, and recover from shocks while maintaining equitable delivery of essential services. We argue that resilience cannot be achieved through disease-specific or short-term humanitarian programmes alone; it requires stronger public stewardship, coordinated federal-state governance, sustainable financing, integrated primary health care, a retained and equitably distributed workforce, interoperable surveillance, and climate-resilient WASH and referral systems. The central recommendation is therefore a transition from fragmented, crisis-driven service delivery toward an accountable, primary-health-care-centred system that links communities, public and private providers, laboratories, referral facilities, and emergency response mechanisms.

PMID 42763727
Read full article →
PubMedInternational journal of women's health2026-09-20

The Impact of Labor-Delivery-Recovery-Postpartum (LDRP) Care Model on Delivery Outcomes: A Single-Center Retrospective Cohort Study.

Ma Bo B, Yu Zelin Z, Mei Na N, Cheng Lan L et al.

This single-center retrospective cohort study compared parturients undergoing delivery under the Labor-Delivery-Recovery-Postpartum (LDRP) model (n=901) with those in traditional delivery rooms (n=2863) to evaluate differences in key obstetric outcomes. The study was conducted at Tianjin Central Maternity and Child Health Hospital (Heping Campus) from July 2023 to August 2024. A total of 3764 eligible parturients (age ≥18 years) were enrolled, with all data systematically extracted from the hospital's electronic medical record system. Collected variables included demographic, obstetric, neonatal, and delivery-related parameters. Given the non-randomized group assignment (based on patient preference and financial capacity), 1:1 propensity score matching (PSM) with a 0.02 caliper was employed to balance baseline characteristics, including maternal age, gestational weeks, epidural analgesia use, parity, complications, neonatal sex, and birth weight, resulting in 900 matched pairs per group. Categorical variables are presented as counts/percentages, and continuous variables as medians with 5th-95th percentile ranges. Post-matching, χ2 -tests compared outcomes, and binary logistic regression identified independent risk factors. After PSM, the LDRP group demonstrated significantly lower rates of vaginal operative delivery (χ2=19.393, p<0.001) and postpartum hemorrhage (χ2=19.498, p<0.001) compared to the traditional delivery group. No significant difference was observed in intrapartum cesarean delivery rates (χ2=0.147, P=0.701). Multivariate analysis identified delivery in a traditional room (OR=1.990, 95% CI 1.478-2.677), along with neonatal birth weight (OR = 1.146, P = 0.016, 95% CI 1.020-1.218) and maternal age (OR = 1.068, P = 0.001, 95% CI 1.026-1.111), as independent risk factors for postpartum hemorrhage. For intrapartum cesarean delivery, independent risk factors included gestational weeks (OR = 1.913, P<0.001, 95% CI 1.485-2.465), number of deliveries (OR = 0.190, P <0.001, 95% CI 0.092-0.394), the presence of complications (OR = 2.358, P<0.001, 95% CI 1.768-3.144) and the duration of labor (OR = 1.059, P<0.001, 95% CI 1.034-1.085). Delivery location was also an independent factor associated with reduced operative vaginal delivery (OR=0.224, 95% CI 0.111-0.454). The findings suggest that the LDRP delivery model is independently associated with a lower incidence of postpartum hemorrhage and operative vaginal delivery. This indicates that the integrated, continuous-care structure of the LDRP model may contribute positively to maternal delivery outcomes and postpartum recovery experience.

PMID 42763665
Read full article →
PubMedInternational journal of nanomedicine2026-09-20

Engineered Exosomal miRNAs for Post-Stroke Neural Repair: Mechanisms, Delivery Strategies, and Translational Challenges.

Xu Shuangfeng S, Tian Daman D, Wang Zhifeng Z, Yang Jiao J et al.

Functional neurological recovery after ischemic stroke remains a formidable challenge in neuroscience. Exosomes serve as pivotal mediators of intercellular communication, and the microRNAs (miRNAs) they carry, in particular, offer a promising "cell-free therapy" strategy for promoting neurological repair. This review systematically summarizes the multi-target mechanisms by which exosomal miRNAs regulate the neurovascular unit (NVU) and outlines technical strategies to enhance exosomal therapeutic efficacy through targeted modification and engineered cargo loading, with the aim of constructing a smart drug delivery system capable of precise navigation. Following the trajectory of "natural exosomes-engineered exosomes-clinical translation", this review addresses the core scientific question of how to transform exosomal miRNAs from natural messenger molecules with basic reparative activity into an intelligent therapeutic system for precise targeted delivery. It further explores precision exosome treatment models based on the pathological staging of stroke progression, and integrates single-cell, spatial transcriptomic, and multi-omics technologies to decode the "miRNA-cell source-target cell-signaling pathway" regulatory axis, thereby identifying candidate miRNA combinations with translational potential. Finally, this review provides an in-depth analysis of the core challenges in translating such nanotherapeutic strategies from the bench to the bedside, including manufacturing standardization, quality control, and potency assessment, with the aim of providing a theoretical basis for advancing exosomal miRNA therapies from mechanistic studies to precision stroke treatment.

PMID 42763691
Read full article →
PubMedInternational journal of nanomedicine2026-09-20

Glutathione-Responsive Disulfiram Delivery from Thiol-Functionalized N-Doped Carbon Nanodots: An in vitro Proof-of-Concept Study.

Panaei Mohadese M, Mahani Mohamad M, Divsar Faten F, Khakbaz Faeze F

To develop and evaluate a glutathione (GSH)-responsive "Off-On" drug delivery system based on thiol-functionalized N-doped carbon dots (SNCDs) for controlled intracellular release of disulfiram (DSF). SNCDs were synthesized using a solvothermal technique and subsequently characterized using dynamic laser scattering, high-resolution electron imaging, UV-Vis spectrophotometry, and Fourier-transform infrared spectroscopy (FTIR). DSF was immobilized onto SNCDs through redox-cleavable disulfide linkages, and loading efficiency was determined by UV-Vis analysis. The in vitro drug release kinetics were examined under simulated physiological (pH 7.4) and tumor-relevant acidic (pH 5.4) conditions, evaluating the impact of glutathione (GSH) by performing experiments with and without its inclusion. Cytotoxicity and compatibility studies in MCF-7 breast tumor cells, evaluated via MTT test, were used to investigate SNCD biocompatibility and the anticancer performance of DSF-SNCDs. The FTIR spectra confirmed effective thiol functionalization and revealed oxygenated and nitrogenous groups on the particle surface suitable for disulfide linkage formation. DSF loading efficiency reached approximately 75%. Under non-reducing conditions, DSF-SNCDs exhibited minimal premature release (≤30% over 24 h at pH 7.4 and 5.4), demonstrating an "Off" state. In contrast, the presence of 5% (w/v) GSH at pH 5.4 triggered rapid DSF release, achieving approximately 80% cumulative release within 24 h, corresponding to the "On" state through reductive disulfide bond cleavage. Bare SNCDs showed high biocompatibility (>85% cell viability at 50 µg/mL), whereas DSF-SNCDs produced significantly enhanced cytotoxicity under GSH conditions, confirming redox-activated drug release. SNCDs provide an effective GSH-responsive nanoplatform for DSF delivery, combining high drug loading, excellent stability under non-reducing conditions, and efficient intracellular drug release under reductive environments. This strategy minimizes premature drug leakage while enhancing anticancer activity, demonstrating strong potential for cancer therapy.

PMID 42763685
Read full article →
PubMedTopics in current chemistry (Cham)2026-09-20

Advances in MOF-Based Transdermal Drug Delivery Systems: Mechanisms, Applications, and Future Prospects.

Ma Deyun D, Guo Sirui S, Liu Ruohan R, Feng Yingzi Y et al.

Transdermal drug delivery offers a noninvasive alternative to conventional administration by avoiding gastrointestinal degradation and hepatic first-pass metabolism. However, its broader clinical application remains limited by the barrier function of the stratum corneum and insufficient drug accumulation within target tissues. Metal-organic frameworks (MOFs), characterized by their high surface area, tunable pore structures, and versatile surface chemistry, have recently emerged as promising platforms for transdermal drug delivery. This review summarizes the key advantages of MOF-based transdermal systems, including high drug-loading capacity, particularly for hydrophobic compounds and macromolecules, programmable multidrug delivery, favorable biocompatibility, and the integration of diagnostic and therapeutic functions with complementary physical treatment modalities. We further discuss recent advances in the rational design of MOF-based transdermal platforms across major biomedical applications, including diabetic wound management, skin regeneration, skin cancer therapy, and cosmetic delivery. Despite these advances, clinical translation remains challenged by insufficient long-term biosafety evaluation, incomplete understanding of degradation behavior and biodistribution, limited manufacturing scalability, and regulatory requirements for complex multifunctional systems. Recent developments in artificial intelligence (AI) provide new opportunities to address several of these challenges by accelerating MOF design, predicting structure-property relationships, optimizing stimuli-responsive drug release, and supporting the development of personalized transdermal therapies. Overall, this review provides an integrated perspective on the design principles, therapeutic applications, and translational challenges of MOF-based transdermal systems, while outlining future directions for their successful clinical development.

PMID 42763813
Read full article →
PubMedOncogene2026-09-20

Beyond the blood-brain barrier: humanised mice, the missing link in glioblastoma research.

Shirazi Nia Reza R, Lu Jian J, De Vega Daniel D, Poudine Niloufar N et al.

Glioblastoma (GBM) remains a major challenge in neuro-oncology, associated with a high rate of mortality despite decades of intensive research and therapeutic advancements, underscoring the urgent need for innovative preclinical platforms that can more accurately recapitulate the biological and pathological features of human disease. While conventional animal models have contributed to our understanding of GBM biology and the evaluation of treatment efficacy, they fail to capture the full complexity and heterogeneity of the tumour microenvironment (TME). Ex vivo models are associated with certain advantages in this context; however, they can not mirror the complex dynamic and multicellular interactions present in living organisms, particularly the critical treatment barriers unique to the central nervous system: the blood-brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB) and blood-meningeal barrier (BMB). In response to these limitations, humanised mouse models have emerged as an advanced platform capable of faithfully mimicking the molecular, pathological and immunological features of human GBM. These models enable the replication of complex in vivo crosstalk between the immune system and the TME, while preserving the relevant treatment barriers that govern drug delivery to the brain. Accumulating evidence indicates that humanised mouse models closely reproduce the infiltration of human immune components into the TME, enabling the study of clinically relevant interactions that contribute to therapeutic resistance and treatment failure in GBM. This review aims to provide a comprehensive and systematic overview of the currently employed humanised mouse models in GBM research, highlighting their applications and comparative advantages. Finally, we evaluate the opportunities and challenges associated with each model and discuss future directions to increase the translational relevance and predictive power of preclinical GBM research. Humanised mouse models provide a valuable translational platform combining the human immune system and PDX orthotopic engraftment. Compared to conventional models and ex vivo models, these models can reproduce the complex cross-talk between tumour cells and the immune system, tumour heterogeneity, immunosuppressive TME, as well as complex in vivo interactions such as brain-specific barriers, including BBB, BCSFB and BMB. Future implementation of the human gut microbiome in these models has the potential to further increase translational relevance and precision in GBM research. Created in BioRender.com.

PMID 42763326
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about OLipHEX delivery system